No differences in chordoma cell PD-L1 positivity, CSC burden, or CSC PD-L1 positivity were identified with clinical correlations of patient age, tumor anatomic site of origin, disease stage, or radiotherapy treatment exposure (Supplementary Figure 2). This evidence concerns the gene CD274 and neoplasm.